XML 43 R32.htm IDEA: XBRL DOCUMENT v3.19.1
Stockholders' Equity (Deficit) (Details Narrative) - USD ($)
3 Months Ended 12 Months Ended
Feb. 20, 2018
Jan. 02, 2017
Mar. 31, 2018
Dec. 31, 2018
Dec. 31, 2017
Dec. 31, 2016
Jan. 24, 2018
Stock options outstanding       3,846,299 3,566,299 2,484,445  
Stock options outstanding weighted average exercise price       $ 1.36 $ 1.33 $ 1.18  
Stock options intrinsic value       $ 2,444,474      
Number of stock options granted       280,000 1,103,000    
Stock option weighted average exercise price per share       $ 1.75 $ 1.68    
Stock options granted, term       8 years 18 days 9 years 9 months 25 days    
Number of stock options vested       972,651 800,456    
Class of warrant or right, outstanding       3,826,658 3,826,658 3,826,658  
Class of warrant or right, outstanding, weighted average exercise price       $ 1.05 $ 1.05 $ 1.05  
Class of warrant or right, outstanding, intrinsic value       $ 3,633,335      
Series B Preferred Stock [Member] | Private Placement [Member]              
Class of warrant or right, number of securities called by warrants or rights       423,291      
Class of warrant or right, exercise price of warrants or rights           $ 1.25  
Class of warrant or right, expiration period       5 years   5 years  
Protagenic Therapeutics Inc [Member]              
Debt instrument, face amount       $ 665,000      
Accrued interest       $ 35,000      
Protagenic Therapeutics Inc [Member] | Predecessor Warrants [Member]              
Class of warrant or right, number of securities called by warrants or rights       295,945      
Class of warrant or right, exercise price of warrants or rights       $ 1.25      
Protagenic Therapeutics Inc [Member] | Placement Agent Warrants [Member]              
Class of warrant or right, number of securities called by warrants or rights       127,346      
Class of warrant or right, exercise price of warrants or rights       $ 1.25      
Protagenic Therapeutics Inc [Member] | Series B Preferred Stock [Member] | Private Placement [Member]              
Class of warrant or right, number of securities called by warrants or rights       3,403,367      
Class of warrant or right, exercise price of warrants or rights       $ 1.05      
Four Consultant [Member]              
Number of stock options granted     80,000        
Stock option granted vesting period     48 months        
Stock options granted, term     10 years        
Number of stock options vested     50,000        
Former Consultant [Member]              
Stock options outstanding weighted average exercise price     $ 1.75        
Consulting Agreement [Member] | Neuro Assets Sarl [Member]              
Share-based compensation arrangement by share-based payment award, number of shares authorized             200,000
Employees [Member]              
Compensation expense       $ 602,479      
Non-Employees [Member]              
Compensation expense       $ 527,592      
Four Consultants [Member] | Over 48 Months [Member]              
Number of stock options vested     30,000        
Stock Option [Member]              
Number of stock options granted       280,000 1,103,000    
Stock option weighted average exercise price per share       $ 1.75 $ 1.25    
Compensation expense       $ 1,130,071 $ 888,281    
Employee Stock Option [Member]              
Employee service share-based compensation, nonvested awards, compensation cost not yet recognized       $ 1,112,084      
Employee service share-based compensation, nonvested awards, compensation cost not yet recognized, period for recognition       2 years 3 months 11 days      
Employee Stock Option [Member] | Employees [Member]              
Employee service share-based compensation, nonvested awards, compensation cost not yet recognized       $ 533,938      
Employee Stock Option [Member] | Non-Employee [Member]              
Employee service share-based compensation, nonvested awards, compensation cost not yet recognized       $ 578,146      
The 2016 Plan [Member]              
Number of additional shares grants for issuance   564,378          
Share-based payment award, expiration period   10 years          
The 2016 Plan [Member] | March 29, 2019 [Member]              
Number of shares available for grant       2,712,678      
2016 Equity Compensation Plan [Member]              
Share-based payment award, expiration period 10 years            
Stock options outstanding weighted average exercise price $ 1.75            
Share-based compensation arrangement by share-based payment award, number of shares authorized 200,000            
Stock option granted vesting period 48 months            
Stock options granted, term 10 years            
2016 Equity Compensation Plan [Member] | Consulting Agreement [Member]              
Share-based compensation arrangement by share-based payment award, number of shares authorized 200,000            
Stock option granted vesting period 48 months            
Stock options granted, term 10 years